GeneDx Holdings WGS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$63.32M-258% | -$17.67M-131% | -$7.64M-171% | $10.81M+266% | -$6.53M— | ||
| $6.81M-1.0% | $6.88M+6.3% | $6.47M+4.6% | $6.19M+9.0% | $5.68M+2.2% | ||
| $9M-8.0% | $9.78M-7.6% | $10.59M+35.5% | $7.81M+96.2% | $3.98M+40.0% | ||
| $897K— | —— | $246K— | —— | $447K+1,963% | ||
| $31.29M— | —— | —— | —— | $0— | ||
| $2.56M-81.0% | $13.43M+4.0% | $12.91M+869% | $1.33M-84.4% | $8.56M— | ||
| -$1.69M-150% | $3.36M— | —— | —— | $2.03M+348% | ||
| -$13.17M-290% | $6.92M— | —— | —— | $10.82M+185% | ||
| $1.03M+32.4% | $781K-21.5% | $995K+57.9% | $630K-16.8% | $757K+16.8% | ||
| -$6.57M— | —— | —— | —— | $0— | ||
| -$32.41M— | $0-100% | $15.77M+51.3% | $10.42M+2.3% | $10.18M+420% | ||
| $6.45M+48.4% | $4.35M-29.6% | $6.17M+161% | $2.37M-61.3% | $6.13M+101% | ||
| $875K-57.6% | $2.06M— | $0— | $0— | $0-100% | ||
| -$17.26M-55.8% | -$11.07M-136% | -$4.69M+87.1% | -$36.35M-286% | -$9.41M-1,713% | ||
| —— | —— | —— | —— | —— | ||
| $476K-54.2% | $1.04M+471% | $182K-77.3% | $800K— | $0-100% | ||
| $495K+31.3% | $377K-58.7% | $912K+65.5% | $551K-9.8% | $611K-50.3% | ||
| $38.59M+66.4% | $23.19M+115% | $10.77M+3,012% | $346K-97.5% | $13.72M-55.8% | ||
| -$11.07M-223% | $9.03M-58.7% | $21.85M+185% | -$25.58M-277% | $14.49M— | ||
| $1.75M+10.8% | $1.58M-2.9% | $1.63M+0.9% | $1.61M+0.6% | $1.6M-2.6% | ||
| $754K+219% | $236K+98.3% | $119K-83.3% | $714K+247% | $206K-19.8% | ||
| $31.29M— | —— | —— | —— | $0— | ||
| -$1.02M— | —— | -$3.73M-3.1% | -$3.62M-159% | -$1.4M— | ||
| $8.5M-15.1% | $10.02M+38.1% | $7.25M-43.2% | $12.78M-8.3% | $13.93M-13.5% | ||
| $875K-57.6% | $2.06M— | $0— | $0— | $0-100% | ||
| $495K+31.3% | $377K-58.7% | $912K+65.5% | $551K-9.8% | $611K-50.3% | ||
| $97M+359% | $21.14M+79.1% | $11.8M— | $0-100% | $13.89M-56.5% | ||
| $5.92M+226% | $1.81M— | —— | $3.56M+61.8% | $2.2M— | ||
| -$2.54M— | —— | $3.4M+256% | -$2.18M-298% | $1.1M-44.4% | ||
| $12.09M— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$38.86M— | —— | $9.6M+19.2% | $8.05M+98.6% | $4.05M+165% | ||
| -$38.86M— | —— | $9.6M+19.2% | $8.05M+98.6% | $4.05M+165% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does GeneDx Holdings generate?
- GeneDx Holdings (WGS) generated -$6.2M in operating cash flow over the trailing twelve months.
- What is GeneDx Holdings's free cash flow?
- After $19.3M of capital expenditures, GeneDx Holdings's free cash flow was -$17.2M over the trailing twelve months, up 49.5% year over year.
- Where does GeneDx Holdings's cash flow data come from?
- Every line is extracted from GeneDx Holdings's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
